Funding & Deals
Sep 08, 2026 · 1 min read · 24,343 views
ADARx targets $319M IPO as TRexBio, Retension join filing queue
L
Liam Turner
Editorial · Sep 08, 2026
ADARx sets terms for a Nasdaq IPO at $15-$17 a share as Treg biotech TRexBio and hypertension player Retension file for their own floats
← Previous
FDA should require credentials for psychedelic providers, experts say
Next →
Compounder Empower receives FDA warning letter over GLP-1s
